The expansion of Lantern Pharma's clinical trial into Japan and Taiwan not only opens up new avenues for research and development but also potentially increases the company's visibility and credibility in the Asian market. Given the significance of this expansion for Lantern Pharma's operations and the involvement of a renowned investigator, this development is likely to be viewed positively by investors and could lead to an uptick in the company's stock price in the short term.